Why Permeasis MTD4 could reshape enzyme replacement and intracellular drug discovery
Discover how Permeasis Therapeutics’ MTD4 platform delivers functional proteins inside cells, and the risks that remain before clinical testing.
Why Theradaptive’s OsteoAdapt could disrupt the $2bn spinal biologics market in 2026
ATEC secures U.S. rights to Theradaptive’s OsteoAdapt. Find out what this deal changes for spinal biologics in 2026 and beyond.